CD274 and breast cancer: In this regard, different combinations of treatments, such as EGFR TKIs with antiangiogenic agents and intrathecal chemotherapy or antiangiogenic therapy with anti-PD-L1 in LM from NSLCLC, as well as intrathecal chemotherapy or ant-PD-L1 with RT in LM from BC, are under investigation in clinical trials (Table 5).